Key result
Ganglioside GD1a increases total megakaryocytes and boosts the ratio of platelet-producing cells to ~12% versus control.
Why the study?
Do specific gangliosides stimulate the maturation of murine megakaryocytes in vitro?
Do specific gangliosides stimulate the maturation of murine megakaryocytes in vitro?
Absolute Event Rate: 12% vs 1%
In a murine in vitro model, ganglioside GD1a stimulates multiple steps of megakaryocyte maturation, whereas GM1 stimulates only the terminal maturation step into platelet-producing cells.
GD1a may stimulate megakaryocyte maturation in murine models; leaves open in vivo or clinical effects on platelet production.
Formation of platelet-producing megakaryocytes, the cytoplasm of which showed the terminal stage of cell maturation, heavy granulation and platelet-fields delineated with demarcation membranes, was observed in a short-term culture system, using megakaryocyte-enriched bone marrow cell suspension. Approximately 6-8% of the megakaryocytes changed to the platelet-producing megakaryocytes during 12-hour incubation. In the presence of inhibitors of energy metabolism, formation of the platelet-producing megakaryocytes was inhibited, suggesting that the process is dependent on energy producing systems. Ganglioside GD1a increased both the number of total megakaryocytes and the ratio of the platelet-producing megakaryocytes to total megakaryocytes, while GM1 did not influence the number of total megakaryocytes, but increased the ratio. Gangliosides GM2, GM3 and GD1b showed little effect on either the number of total megakaryocytes or the ratio. The results suggest that ganglioside GD1a stimulates at least two steps of megakaryocyte maturation, the change of megakaryocytic progenitors to megakaryocytes and the subsequent maturation of megakaryocytes to the platelet-producing megakaryocytes, while GM1 stimulates only the latter step of the maturation.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (1990) studied Megakaryocyte maturation. Gangliosides (GD1a, GM1) vs. Control medium was evaluated on Ratio of platelet-producing megakaryocytes to total megakaryocytes. Ganglioside GD1a increased both the total number of megakaryocytes and the ratio of platelet-producing megakaryocytes (reaching approximately 12% compared to 1% in control), whereas GM1 increased only the ratio.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: